LP Pharmaceuticals   Report issue

For profit Phase 3
Founded: Xiamen China (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2020
NCT04592198
First Marketed Drug
2017
clonidine (catapres)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Xiamen LP Pharmaceutical Co., Ltd | XIAMEN LP PHARM CO

Active Ingredients

Marketed Drugs (5)

clonidine (catapres) (2017)

donepezil (aricept) (2023)

memantine (namenda) (2022)

pramipexole (mirapex) (2021)

topiramate (topamax) (2022)

Drugs in Phase 3 Trials (1)

palonosetron (aloxi) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Nausea (Phase 2)

Vomiting (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1